{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:08:04Z","timestamp":1791180484660,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,1,22]],"date-time":"2009-01-22T00:00:00Z","timestamp":1232582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00213-008-1452-9","type":"journal-article","created":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T06:10:35Z","timestamp":1232518235000},"page":"241-250","source":"Crossref","is-referenced-by-count":51,"title":["Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats"],"prefix":"10.1007","volume":"204","author":[{"given":"C.","family":"Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Rodr\u00edguez-Oroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. D.","family":"Bartoszyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Obeso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,1,22]]},"reference":[{"key":"1452_CR1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366\u2013375","journal-title":"Trends Neurosci"},{"key":"1452_CR2","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/brain\/awl103","volume":"129","author":"F Alonso-Frech","year":"2006","unstructured":"Alonso-Frech F, Zamarbide I, Alegre M, Rodr\u00edguez-Oroz MC, Guridi J, Manrique M, Valencia M, Artieda J, Obeso JA (2006) Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson\u2019s disease. Brain 129:1748\u20131757","journal-title":"Brain"},{"key":"1452_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1113\/jphysiol.1987.sp016862","volume":"394","author":"R Andrade","year":"1987","unstructured":"Andrade R, Nicoll RA (1987) Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro. J Physiol 394:99\u2013124","journal-title":"J Physiol"},{"key":"1452_CR4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/syn.20195","volume":"58","author":"T Antonelli","year":"2005","unstructured":"Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S, Ferraro J (2005) Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58:193\u2013199","journal-title":"Synapse"},{"key":"1452_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-8993(94)91511-3","volume":"667","author":"R Arai","year":"1994","unstructured":"Arai R, Karasaw N, Geffard M, Nagatsu T, Nagatsu I (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous l-dopa in the rat, with reference to involvement of aromatic l-amino acid decarboxylase. Brain Res 667:295\u2013299","journal-title":"Brain Res"},{"key":"1452_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0006-8993(96)00252-1","volume":"722","author":"R Arai","year":"1996","unstructured":"Arai R, Karasawa N, Nagatsu I (1996) Dopamine produced form l-Dopa is degraded by endogenous monoamine oxidase in neurons of the dorsal raphe nucleus of the rat: an immunohistochemical study. Brain Res 722:181\u2013184","journal-title":"Brain Res"},{"key":"1452_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.brainres.2006.10.020","volume":"1127","author":"M Ba","year":"2007","unstructured":"Ba M, Kong M, Ma G, Yang H, Lu G, Chen S, Liu Z (2007) Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications. Brain Res 1127:177\u2013184","journal-title":"Brain Res"},{"key":"1452_CR8","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","volume":"20","author":"W Bara-Jimenez","year":"2005","unstructured":"Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitriva T, Sherzai A, Mouradian MM, Chase TN (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson\u2019s disease. Mov Disord 20:932\u2013936","journal-title":"Mov Disord"},{"key":"1452_CR9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","volume":"38","author":"NM Barnes","year":"1999","unstructured":"Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083\u20131152","journal-title":"Neuropharmacology"},{"issue":"Suppl 15","key":"1452_CR10","first-page":"S572","volume":"21","author":"GD Bartoszyk","year":"2006","unstructured":"Bartoszyk GD (2006) Mechanism of antidyskinetic action of sarizotan: a basal ganglia circuitry hypothesis. Mov Disord 21(Suppl 15):S572\u2013573","journal-title":"Mov Disord"},{"key":"1452_CR11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00702-003-0094-7","volume":"111","author":"GD Bartoszyk","year":"2004","unstructured":"Bartoszyk GD, van Amsterdam C, Greiner HE, Rautenberg W, Russ H, Seyfried CA (2004) Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 111:113\u2013126","journal-title":"J Neural Transm"},{"issue":"Suppl 2","key":"1452_CR12","first-page":"241","volume":"11","author":"GD Bartoszyk","year":"2005","unstructured":"Bartoszyk GD, Kuzhikandathil EV (2005) Receptor pharmacology of the antidyskinetic drug sarizotan. Parkinsonism Relat Disord 11(Suppl 2):241","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 15","key":"1452_CR13","first-page":"S495","volume":"21","author":"GD Bartoszyk","year":"2006","unstructured":"Bartoszyk GD, van den Buuse M, Gerlach M, Riederer P (2006) Mechanism of the antidyskinetic efficacy of sarizotan in hemiparkinsonian rats. Mov Disord 21(Suppl 15):S495","journal-title":"Mov Disord"},{"key":"1452_CR14","unstructured":"Bedard PJ, Gregoire L, Samadi P, Bartoszyk GD, Di Paolo T (2006) Sarizotan reduces dyskinesia and maintains antiparkinsonian efficacy of levodopa in MPTP monkeys. Soc Neurosci Abstract no. 175.10"},{"key":"1452_CR15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1152\/jn.1994.72.2.507","volume":"72","author":"H Bergman","year":"1994","unstructured":"Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72:507\u2013520","journal-title":"J Neurophysiol"},{"key":"1452_CR16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","volume":"2","author":"E Bezard","year":"2001","unstructured":"Bezard E, Brotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature Rev Neurosci 2:577\u2013588","journal-title":"Nature Rev Neurosci"},{"key":"1452_CR17","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"F Bibbiani","year":"2001","unstructured":"Bibbiani F, Oh JD, Chase TN (2001) Sarizotan 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57:1829\u20131834","journal-title":"Neurology"},{"key":"1452_CR18","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/j.1460-9568.2006.04790.x","volume":"23","author":"C Bishop","year":"2006","unstructured":"Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD (2006) MDMA and fenfluramine reduce l-dopa-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur J Neurosci 23:2669\u20132676","journal-title":"Eur J Neurosci"},{"key":"1452_CR19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1749-6632.1998.tb10192.x","volume":"861","author":"P Blier","year":"1998","unstructured":"Blier P, Pneyro G, El Mansari M, Bergeron R, De Montigny C (1998) Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann NY Acad Sci 861:204\u2013216","journal-title":"Ann NY Acad Sci"},{"key":"1452_CR20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0006-8993(76)90050-0","volume":"113","author":"P Bobillier","year":"1976","unstructured":"Bobillier P, Seguin S, Petijean F, Salvert D, Touret M, Jouvet M (1976) The raphe nuclei of the cat brain stem: a topographical atlas of their efferent projections as revealed by autoradiography. Brain Res 113:449\u2013486","journal-title":"Brain Res"},{"key":"1452_CR21","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1111\/j.1460-9568.2006.05106.x","volume":"24","author":"S Breit","year":"2006","unstructured":"Breit S, Lessmann L, Unterbrink D, Popa RC, Gasser T, Schulz JB (2006) Lesion of the pedunculopontine nucleus reverses hyperactivity of the subthalamic nucleus and substantia nigra pars reticulata in a 6-hydroxydopamine rat model. Eur J Neurosci 24:2275\u20132282","journal-title":"Eur J Neurosci"},{"key":"1452_CR22","first-page":"8011","volume":"27","author":"T Carlsson","year":"2007","unstructured":"Carlsson T, Carta M, Winkler C, Bj\u00f6rklund A, Kirik D (2007) Serotonin neuron transplants exacerbate-dopa-induced dyskinesias in a rat model of Parkinson\u2019s disease. Neurobiol Dis 27:8011\u20138022","journal-title":"Neurobiol Dis"},{"key":"1452_CR23","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bj\u00f6rklund A (2007) Dopamine released from 5-HT terminals is the cause of l-dopa-induced dyskinesia in parkinsonian rats. Brain 130:1819\u20131833","journal-title":"Brain"},{"key":"1452_CR24","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","volume":"10","author":"MA Cenci","year":"1998","unstructured":"Cenci MA, Lee CS, Bj\u00f6klund A (1998) l-Dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynophin-and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694\u20132706","journal-title":"Eur J Neurosci"},{"key":"1452_CR25","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/j.1460-9568.2004.03629.x","volume":"20","author":"SJ Cragg","year":"2004","unstructured":"Cragg SJ, Baufreton J, Xue Y, Bolam JP, Bevan MD (2004) Restricted, synaptic release of dopamine in the subthalamic nucleus of the rat. Synaptic release of dopamine in the subthalamic nucleus. Eur J Neurosci 20:1788\u20131802","journal-title":"Eur J Neurosci"},{"key":"1452_CR26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0006-8993(87)90861-4","volume":"423","author":"MF Davies","year":"1987","unstructured":"Davies MF, Deisz RA, Prince DA, Peroutka SJ (1987) Two distinct effects of 5-hydroxytryptamine on single cortical neurons. Brain Res 423:347\u2013352","journal-title":"Brain Res"},{"key":"1452_CR27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of l-dopa-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76\u201389","journal-title":"Behav Brain Res"},{"key":"1452_CR28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","volume":"13","author":"MR DeLong","year":"1990","unstructured":"DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281\u2013285","journal-title":"Trends Neurosci"},{"key":"1452_CR29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1152\/jn.1985.53.2.530","volume":"53","author":"MR DeLong","year":"1985","unstructured":"DeLong MR, Crutcher MD, Georgopoulos AP (1985) Primate globus pallidus and subthalamic nucleus: functional organization. J Neurophysiol 53:530\u2013543","journal-title":"J Neurophysiol"},{"key":"1452_CR30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainres.2007.05.005","volume":"1158","author":"KB Dupre","year":"2007","unstructured":"Dupre KB, Eskow KL, Negron G, Bishop C (2007) The differential effects of 5-HT1A receptor-stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 1158:135\u2013143","journal-title":"Brain Res"},{"key":"1452_CR31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00213-008-1135-6","volume":"199","author":"KB Dupre","year":"2008","unstructured":"Dupre KB, Eskow KL, Steiniger A, Kiloueva A, Negron GE, Lormand L, Park JY, Bishop C (2008) Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-dopa-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology 199:99\u2013108","journal-title":"Psychopharmacology"},{"key":"1452_CR32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","volume":"87","author":"KL Eskow","year":"2007","unstructured":"Eskow KL, Gupta V, Alam S, Park JY, Bishop C (2007) The partial 5-HT1A agonist buspirone reduces the expression and development of l-dopa-induced dyskinesia in rats and improves L-dopa efficacy. Pharmacol Biochem Behav 87:306\u2013314","journal-title":"Pharmacol Biochem Behav"},{"issue":"Suppl. 13","key":"1452_CR33","first-page":"S71","volume":"21","author":"M Gerlach","year":"2006","unstructured":"Gerlach M, Bartoszyk GD, van den Buuse M, Schwarz J, Riederer P (2006a) Antidyskinetic efficacy of sarizotan. Mov Disord 21(Suppl. 13):S71\u201372","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"1452_CR34","first-page":"S121","volume":"9","author":"M Gerlach","year":"2006","unstructured":"Gerlach M, van den Buuse M, Bartoszyk G, Riederer P (2006b) Mechanism of the antidyskinetic efficacy of sarizotan in hemiparkinsonian rats. Int J Neuropsychopharmacol 9(Suppl 1):S121","journal-title":"Int J Neuropsychopharmacol"},{"key":"1452_CR35","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0022-3565(25)09547-3","volume":"273","author":"A Gobert","year":"1995","unstructured":"Gobert A, Lejeune F, Rivet JM, Audinot V, Newman-Tancredi A, Millan MJ (1995) Modulation of the activity of central serotoninergic neurons by novel serotonin 1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats. J Pharmacol Exp Ther 273:1032\u20131046","journal-title":"J Pharmacol Exp Ther"},{"key":"1452_CR36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","volume":"20","author":"XG Goetz","year":"2005","unstructured":"Goetz XG, Poewe W, Rascol O, Sampaio C (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson\u2019s disease: 2001\u20132004. Mov Disord 20:523\u2013539","journal-title":"Mov Disord"},{"key":"1452_CR37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/brain\/awh029","volume":"127","author":"C Hamani","year":"2004","unstructured":"Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM (2004) The subthalamic nucleus in the context of movement disorders. Brain 127:4\u201320","journal-title":"Brain"},{"key":"1452_CR38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0006-8993(96)01167-5","volume":"749","author":"OK Hassani","year":"1997","unstructured":"Hassani OK, Francois C, Yelnik J, Feger J (1997) Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat. Brain Res 749:88\u201394","journal-title":"Brain Res"},{"key":"1452_CR39","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1152\/jn.00664.2006","volume":"96","author":"A Hern\u00e1ndez","year":"2006","unstructured":"Hern\u00e1ndez A, Ib\u00e1\u00f1ez-Sandoval O, Sierra A, Valdiosera R, Tapia D, Anaya V, Galarraga E, Bargas J, Aceves J (2006) Control of the subthalamic innervation of the rat globus pallidus by D2\/3 and D4 dopamine receptors. J Neurophysiol 96:2877\u20132888","journal-title":"J Neurophysiol"},{"key":"1452_CR40","first-page":"13","volume":"3","author":"O Hornykiewicz","year":"1975","unstructured":"Hornykiewicz O (1975) Monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser 3:13\u201321","journal-title":"Natl Inst Drug Abuse Res Monogr Ser"},{"key":"1452_CR41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","volume":"71","author":"D Hoyer","year":"2002","unstructured":"Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533\u2013554","journal-title":"Pharmacol Biochem Behav"},{"issue":"Suppl 11","key":"1452_CR42","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations. Mov Disord 20(Suppl 11):S11\u2013S16","journal-title":"Mov Disord"},{"key":"1452_CR43","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1471-4159.2001.00184.x","volume":"76","author":"K Kannari","year":"2001","unstructured":"Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M (2001) Activation of 5-HT1A, but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-dopa in the striatum with nigrostriatal denervation. J Neurochem 76:1346\u20131353","journal-title":"J Neurochem"},{"key":"1452_CR44","first-page":"120","volume":"131","author":"SJ Kish","year":"2008","unstructured":"Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease. Brain 131:120\u2013131","journal-title":"Brain"},{"key":"1452_CR45","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0022-3565(25)38872-5","volume":"269","author":"DS Kreiss","year":"1994","unstructured":"Kreiss DS, Lucki I (1994) Differential regulation of serotonin (5-HT) release in the striatum and hippocampus by 5-HT1A autoreceptors of the dorsal and median raphe nuclei. J Pharmacol Exp Ther 269:1268\u20131279","journal-title":"J Pharmacol Exp Ther"},{"key":"1452_CR46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/bdd.558","volume":"28","author":"S Kr\u00f6sser","year":"2007","unstructured":"Kr\u00f6sser S, Neugebauer R, Chassard D, Kovar A (2007) Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. Biopharm Drug Dispos 28:339\u2013347","journal-title":"Biopharm Drug Dispos"},{"key":"1452_CR47","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.neuropharm.2006.05.030","volume":"51","author":"EV Kuzhikandathil","year":"2006","unstructured":"Kuzhikandathil EV, Bartoszyk GD (2006) The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors. Neuropharmacology 51:873\u2013884","journal-title":"Neuropharmacology"},{"key":"1452_CR48","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/j.1460-9568.2004.03244.x","volume":"19","author":"JL Lanciego","year":"2004","unstructured":"Lanciego JL, Gonzalo N, Castle M, Sanchez-Escobar C, Aymerich MS, Obeso JA (2004) Thalamic innervation of striatal and subthalamic neurons projecting to the rat entopeduncular nucleus. Eur J Neurosci 19:1267\u20131277","journal-title":"Eur J Neurosci"},{"key":"1452_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cne.902990102","volume":"299","author":"B Lavoie","year":"1990","unstructured":"Lavoie B, Parent A (1990) Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 299:1\u201316","journal-title":"J Comp Neurol"},{"key":"1452_CR50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1152\/jn.2001.86.1.249","volume":"86","author":"R Levy","year":"2001","unstructured":"Levy R, Dostrovsky JO, Lang AE, Sime E, Hutchinson WD, Lozano AM (2001) Effects of apomorphine on subthalamic nucleus and globus pallidus pars interna in patients with Parkinson\u2019s disease. J Neurophysiol 86:249\u2013260","journal-title":"J Neurophysiol"},{"key":"1452_CR51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.brainres.2007.02.052","volume":"1149","author":"J Liu","year":"2007","unstructured":"Liu J, Chu YX, Zhang QJ, Wang S, Feng J, Li Q (2007) 5.7-Dihydroxytryptamine lesion of the dorsal raphe nucleus alters neuronal activity of the subthalamic nucleus in normal and 6-hydroxydopamine-lesioned rats. Brain Res 1149:216\u2013222","journal-title":"Brain Res"},{"key":"1452_CR52","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","volume":"194","author":"M Lunblad","year":"2005","unstructured":"Lunblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA (2005) Pharmacological validation of a mouse model of l-dopa-induced dyskinesia. Exp Neurol 194:66\u201375","journal-title":"Exp Neurol"},{"key":"1452_CR53","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.brainres.2005.04.019","volume":"1046","author":"T Maeda","year":"2005","unstructured":"Maeda T, Nagata K, Yoshida Y, Kannari K (2005) Serotoninergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-dopa. Brain Res 1046:230\u2013233","journal-title":"Brain Res"},{"key":"1452_CR54","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/mds.20780","volume":"21","author":"C Marin","year":"2006","unstructured":"Marin C, Aguilar E, Obeso JA (2006) Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsnian rats. Mov Dis 21:646\u2013653","journal-title":"Mov Dis"},{"key":"1452_CR55","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1152\/jn.1992.67.6.1615","volume":"67","author":"M Matsumara","year":"1992","unstructured":"Matsumara M, Kojima J, Gardiner TW, Hikosaka O (1992) Visual and oculomotor functions of monkey subthalamic nucleus. J Neurophysiol 67:1615\u20131632","journal-title":"J Neurophysiol"},{"key":"1452_CR56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0304-3940(85)90566-X","volume":"62","author":"S Mori","year":"1985","unstructured":"Mori S, Takino T, Yamada H, Sano Y (1985) Imunohistochemical demonstration of serotonin nerve fibers in the subthalamic nucleus of the rat, cat and monkey. Neurosci Lett 62:305\u2013309","journal-title":"Neurosci Lett"},{"key":"1452_CR57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1152\/jn.2000.84.1.289","volume":"84","author":"A Nambu","year":"2000","unstructured":"Nambu A, Tokuno H, Hamada I, Kita H, Imanishi M, Akazawa J, Ikeuchi Y, Hasegawa N (2000) Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol 84:289\u2013300","journal-title":"J Neurophysiol"},{"key":"1452_CR58","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.170.3953.76","volume":"170","author":"KY Ng","year":"1970","unstructured":"Ng KY, Chase TN, Colburn RW, Kopin IJ (1970) l-Dopa-induced release of cerebral monoamines. Science 170:76\u201377","journal-title":"Science"},{"key":"1452_CR59","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/230331a0","volume":"230","author":"KY Ng","year":"1971","unstructured":"Ng KY, Colburn RW, Kopin IJ (1971) Effects of L-dopa on efflux of cerebral monamines from synaptosomes. Nature 230:331\u2013332","journal-title":"Nature"},{"issue":"10 Suppl","key":"1452_CR60","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","volume":"23","author":"JA Obeso","year":"2000","unstructured":"Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson\u2019s disease. Trends Neurosci 23(10 Suppl):S2\u2013S7","journal-title":"Trends Neurosci"},{"key":"1452_CR61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","volume":"27","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Damier P, Goetz CG et al (2004) Multicenter, open-label, trial of sarizotan in Parkinson\u2019s disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27:58\u201362","journal-title":"Clin Neuropharmacol"},{"key":"1452_CR62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","volume":"662","author":"SM Papa","year":"1994","unstructured":"Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69\u201374","journal-title":"Brain Res"},{"key":"1452_CR63","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"1986","unstructured":"Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic, New York"},{"key":"1452_CR64","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0169-328X(94)90223-2","volume":"23","author":"M Pompeiano","year":"1994","unstructured":"Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2c receptors. Mol Brain Res 23:163\u2013178","journal-title":"Mol Brain Res"},{"key":"1452_CR65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/026988110201600301","volume":"16","author":"EA Rabiner","year":"2002","unstructured":"Rabiner EA, Gunn RN, Wilkins R, Sedman E, Grasby PM (2002) Evaluation of EMD 128130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J Psychopharmacol 16:195\u2013199","journal-title":"J Psychopharmacol"},{"key":"1452_CR66","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484\u20131491","journal-title":"N Engl J Med"},{"key":"1452_CR67","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/(SICI)1097-4547(19980601)52:5<591::AID-JNR11>3.0.CO;2-5","volume":"52","author":"M Santiago","year":"1998","unstructured":"Santiago M, Matarredona ER, Machado A, Cano J (1998) Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum. J Neurosci Re 52:591\u2013598","journal-title":"J Neurosci Re"},{"key":"1452_CR68","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"A Schrag","year":"2000","unstructured":"Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson\u2019s disease: a community-based study. Brain 123:2297\u20132305","journal-title":"Brain"},{"key":"1452_CR69","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.neuropharm.2005.09.003","volume":"49","author":"IM Standford","year":"2005","unstructured":"Standford IM, Kantaria MA, Chahal KC, Loucif CL (2005) 5-Hydroxytryptamine induced excitation and inhibition in the subthalamic nucleus: action at 5-HT2C, 5-HT4 and 5-HT1A receptors. Neuropharmacology 49:1228\u20131234","journal-title":"Neuropharmacology"},{"key":"1452_CR70","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","volume":"10","author":"H Tanaka","year":"1999","unstructured":"Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M (1999) Role of serotoninergic neurons in L-Dopa-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10:631\u2013634","journal-title":"Neuroreport"},{"key":"1452_CR71","first-page":"S131","volume":"47","author":"JL Vitek","year":"2000","unstructured":"Vitek JL, Giroux M (2000) Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann Neurol 47:S131\u2013S140","journal-title":"Ann Neurol"},{"key":"1452_CR72","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0959-4388(96)80024-9","volume":"6","author":"T Whichmann","year":"1996","unstructured":"Wichmann T, DeLong MR (1996) Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 6:751\u2013758","journal-title":"Curr Opin Neurobiol"},{"key":"1452_CR73","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1749-6632.2003.tb07477.x","volume":"991","author":"T Wichmann","year":"2003","unstructured":"Wichmann T, DeLong MR (2003) Pathophysiology of Parkinson\u2019s disease: the MPTP primate model of the huma disorder. Ann NY Acad Sci 991:199\u2013213","journal-title":"Ann NY Acad Sci"},{"key":"1452_CR74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","volume":"10","author":"Ch Winkler","year":"2002","unstructured":"Winkler Ch, Kirik D, Bj\u00f6rklund A Cenci A (2002) l-Dopa-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson\u2019s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165\u2013186","journal-title":"Neurobiol Dis"},{"key":"1452_CR75","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/cne.903510304","volume":"351","author":"DE Wright","year":"1995","unstructured":"Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jennes L (1995) Comparative localization of serotonin 1 A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol 351:357\u2013373","journal-title":"J Comp Neurol"},{"key":"1452_CR76","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1152\/jn.00561.2004","volume":"93","author":"Z Xiang","year":"2005","unstructured":"Xiang Z, Kitai ST (2005) Modulation of spontaneous firing in rat subthalamic neurons by 5-HT receptor subtypes. J Neurophysiol 93:1145\u20131157","journal-title":"J Neurophysiol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-008-1452-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-008-1452-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-008-1452-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T02:47:00Z","timestamp":1738896420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-008-1452-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,22]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["1452"],"URL":"https:\/\/doi.org\/10.1007\/s00213-008-1452-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,22]]}}}